Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.81 -0.1%	$12.60	$8.04 ▼ $45.00	$347.41M	3.41	454,579 shs	293,240 shs
GPCR Structure Therapeutics	$27.00 +4.2%	$20.28	$13.22 ▼ $62.74	$1.55B	-1.35	920,278 shs	1.50 million shs
OCUL Ocular Therapeutix	$8.30 +1.1%	$7.29	$4.79 ▼ $11.78	$1.32B	1.49	1.46 million shs	1.00 million shs
SPRY ARS Pharmaceuticals	$13.97 +0.4%	$12.66	$7.55 ▼ $18.51	$1.37B	0.86	1.18 million shs	1.03 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+5.34%	+10.71%	-23.87%	-51.86%
GPCR Structure Therapeutics	+9.70%	+12.46%	+31.06%	-15.74%	-33.63%
OCUL Ocular Therapeutix	+0.98%	+3.79%	+8.31%	+4.72%	+71.04%
SPRY ARS Pharmaceuticals	-1.56%	-7.20%	+11.45%	-2.79%	+61.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8089 of 5 stars	4.6	0.0	0.0	2.5	2.5	0.6
GPCR Structure Therapeutics	2.3571 of 5 stars	3.5	1.0	0.0	3.9	1.7	0.6
OCUL Ocular Therapeutix	3.5926 of 5 stars	3.4	1.0	4.1	3.3	1.7	0.0
SPRY ARS Pharmaceuticals	3.1181 of 5 stars	3.6	2.0	0.0	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.13	Buy	$59.20	362.14% Upside
GPCR Structure Therapeutics	3.00	Buy	$81.29	201.06% Upside
OCUL Ocular Therapeutix	2.89	Moderate Buy	$16.38	97.29% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	121.90% Upside

Current Analyst Ratings Breakdown

Latest ARCT, SPRY, GPCR, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/11/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00
3/7/2025	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$58.00 ➝ $50.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$138.39M	2.51	N/A	N/A	$10.42 per share	1.23
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
OCUL Ocular Therapeutix	$63.72M	20.71	N/A	N/A	$0.79 per share	10.51
SPRY ARS Pharmaceuticals	$89.15M	15.38	N/A	N/A	$2.40 per share	5.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$3.01	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	5/12/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.79	N/A	N/A	N/A	N/A	-16.37%	-15.68%	5/8/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.26	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	5/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	-$54.37M	$0.08	N/A	N/A	N/A	N/A	-22.56%	-21.82%	5/8/2025 (Estimated)

Latest ARCT, SPRY, GPCR, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.10	N/A	N/A	N/A	$25.64 million	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	N/A	N/A	N/A	$7.48 million	N/A
5/5/2025	Q1 2025	OCUL Ocular Therapeutix	-$0.28	N/A	N/A	N/A	$17.02 million	N/A
3/20/2025	Q4 2024	SPRY ARS Pharmaceuticals	-$0.04	$0.52	+$0.56	$0.52	$15.46 million	$86.58 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.58%	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
GPCR Structure Therapeutics	N/A	27.63	27.63
OCUL Ocular Therapeutix	0.19	13.01	12.94
SPRY ARS Pharmaceuticals	N/A	12.56	12.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
GPCR Structure Therapeutics	91.78%
OCUL Ocular Therapeutix	59.21%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	15.30%
GPCR Structure Therapeutics	9.43%
OCUL Ocular Therapeutix	3.50%
SPRY ARS Pharmaceuticals	40.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
OCUL Ocular Therapeutix	230	159.02 million	151.71 million	Optionable
SPRY ARS Pharmaceuticals	90	98.12 million	58.21 million	Optionable

ARCT, SPRY, GPCR, and OCUL Headlines

Recent News About These Companies

ARS Pharmaceuticals Has A Blockbuster Candidate

April 30 at 7:04 AM | seekingalpha.com

Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $31.00

April 30 at 1:11 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from Analysts

April 28 at 2:08 AM | marketbeat.com

Raymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 26, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Trexquant Investment LP

April 15, 2025 | marketbeat.com

ExodusPoint Capital Management LP Buys Shares of 24,628 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 15, 2025 | marketbeat.com

Vanguard Group Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 15, 2025 | marketbeat.com

Laura Shawver Sells 50,002 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

April 10, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares

April 9, 2025 | insidertrades.com

Sei Investments Co. Invests $1.14 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 9, 2025 | marketbeat.com

Franklin Resources Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 8, 2025 | marketbeat.com

Alliancebernstein L.P. Has $40.94 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

April 7, 2025 | marketbeat.com

ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money

April 6, 2025 | msn.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Should You Buy?

April 4, 2025 | marketbeat.com

AssuredPartners Investment Advisors LLC Takes $312,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

March 30, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year

March 26, 2025 | finance.yahoo.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript

March 22, 2025 | insidermonkey.com

Scotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

March 22, 2025 | markets.businessinsider.com

ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

March 22, 2025 | msn.com

Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 13.63%

March 22, 2025 | aaii.com

ARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)

March 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, SPRY, GPCR, and OCUL Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.81 -0.01 (-0.08%)

As of 04:00 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Structure Therapeutics NASDAQ:GPCR

$27.00 +1.09 (+4.21%)

As of 04:00 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$8.30 +0.09 (+1.10%)

As of 04:00 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$13.97 +0.05 (+0.36%)

As of 04:00 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time